GlassScriptPhysician profile
Kevin Scott Sieja
NPI 1952356677
$10,209.62
in general payments reported to CMS, 2019-2025
42 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,358 · 2020: $550 · 2021: $690 · 2022: $1,677 · 2023: $2,692 · 2024: $1,885 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,934.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,055.21 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,540.95 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $959.05 | 2019-2025 | |
| Janssen Biotech, INC. | $666.19 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Gastrogpo, LLC | $540.00 | 2023 | |
| Pfizer INC. | $461.94 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $430.79 | 2022-2025 | Dupixent |
| Celgene Corporation | $398.87 | 2021-2024 | Zeposia |
| Genzyme Corporation | $320.58 | 2022-2025 | |
| Lilly USA, LLC | $309.40 | 2023-2025 | Omvoh |
| Boston Scientific Corporation | $259.73 | 2023 | Cre Pro |
| Braintree Laboratories, INC. | $248.74 | 2019-2025 | Suflave |
| Ucb, INC. | $181.52 | 2019-2020 | |
| Organon LLC | $163.78 | 2022-2024 | Renflexis, Hadlima |
| Nestle Healthcare Nutrition INC. | $160.85 | 2021-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $140.27 | 2019-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.73 | 2019-2024 | Xifaxan, Trulance |
| Qol Medical, LLC | $136.80 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $118.11 | 2024-2025 | Iqirvo |
| Celltrion USA INC. | $109.71 | 2024-2025 | Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.44 | 2023-2024 | Cyltezo |
| Ferring Pharmaceuticals INC. | $85.16 | 2019-2023 | Rebyota |
| Fresenius Kabi USA, LLC | $76.09 | 2023 | Idacio |
| Merck Sharp & Dohme LLC | $70.21 | 2019-2023 | Dificid |
| Echosens North America, INC. | $56.71 | 2019-2024 | Fibroscan |
| Alfasigma USA, INC. | $52.63 | 2020-2021 | |
| Amgen INC. | $52.46 | 2020-2023 | Amjevita, Avsola |
| Aimmune Therapeutics, INC. | $43.03 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $34.89 | 2024-2025 | Voquezna |
| Laborie Medical Technologies Corp. | $33.11 | 2024 | |
| Shionogi INC | $32.04 | 2020 | |
| Daiichi Sankyo INC. | $30.09 | 2023 | Injectafer |
| Madrigal Pharmaceuticals | $28.99 | 2024 | Resmetirom |
| Allergan, INC. | $27.46 | 2019-2020 | |
| Ethicon US, LLC | $26.66 | 2019 | |
| Medtronic, INC. | $25.19 | 2025 | Pillcam |
| Mirum Pharmaceuticals, INC. | $20.35 | 2024 | Livmarli |
| E.R. Squibb & Sons, L.L.C. | $20.04 | 2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $20.00 | 2023 | Linzess |
| Invivyd INC | $16.74 | 2025 | Pemgarda |
| Ardelyx, INC. | $15.01 | 2025 | Ibsrela |
| Novo Nordisk INC | $14.10 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,517.92 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Sieja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.